Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 2;47(12):zsae148. doi: 10.1093/sleep/zsae148

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of Sleep Research Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Maintenance of Wakefulness Test (MWT) sleep onset latency (SOL) and microsleep metrics by treatment group and day for participants with narcolepsy type 1 (NT1) (A, C, E) and narcolepsy type 2 (NT2; B, D, F). SOL (A, B) shows a clear treatment effect. A siesta effect was apparent at 02:00 pm in NT1 and NT2, also visible without treatment. Microsleep rate (C, D) decreases greatly during treatment, with microsleeps basically eliminated on day 1. Microsleep duration (E, F) is also reduced in the NT1 cohort. Cohort values: Bp, T1 placebo; B1, NT1 11 mg danavorexton; B2, NT1 44 mg danavorexton; Cp, NT2 placebo; C1, NT2 44 mg danavorexton; C2, NT2 112 mg danavorexton. One epoch, 30 seconds.